Cytocast

Cytocast is a techbio startup that uses AI-powered predictive modeling and Digital Twin technology to evaluate the side effects of chemical compounds in pharmaceutical research. By creating realistic, dynamic computer simulations of human cells capable of modeling billions of molecular interactions per second, Cytocast helps drug discovery and preclinical teams prioritize the most promising drug candidates earlier, reducing time, cost, and risk throughout the development pipeline.

The company's core offering, the Cytocast Digital Twin Platform™, underpins a suite of three specialized products designed to support decision-making at distinct stages of drug discovery and preclinical development. Each product delivers interactive reports, adverse event analyses, and mechanistic explanations to enable evidence-based candidate selection and help pharmaceutical teams avoid costly late-stage failures.

Core Products

• Cytocast SCREENER™ — Designed for use in the dry lab phase, before new syntheses are undertaken. It efficiently clusters hundreds to thousands of compounds while flagging potential side-effect liabilities, enabling research teams to eliminate weaker candidates earlier in the process. By facilitating rapid "fail fast" decisions, Screener significantly reduces the time and costs associated with pursuing suboptimal compounds. It provides interactive reports detailing potential side effects and helps teams focus resources on compounds with the highest probability of success.
• Cytocast OPTIMIZER™ — Applied during early and late-phase preclinical studies. Following in vitro and in vivo testing, Optimizer refines candidate selection by enriching understanding with comprehensive adverse event analyses and comparative assessments. It delivers actionable insights on prioritized candidates, including detailed mechanistic explanations that may underlie predicted side effects, and optionally incorporates secondary pharmacology data to support confident down-selection decisions. This module helps teams eliminate unworthy candidates before costly late-stage development and reduces the time and resources required to arrive at a final selection.
• Cytocast NOMINATOR™ — Used at the stage of selecting "lead" and "backup" candidates. Nominator provides sophisticated, fully interactive reports that quantify adverse-event risk profiles with unparalleled depth for final candidates, optimizing clinical trial decision-making. It features optional drug–drug interaction predictions and safety profile comparisons against competing therapies to de-risk lead nomination. Comprehensive reports and detailed outcome analyses enable pharmaceutical companies to optimize clinical trial design and execution with greater confidence in candidate selection.

Technology and Methodology

• Cytocast uses computer simulations — its Digital Twin Platform — to determine the most effective treatments for patients while minimizing potential side effects.
• The platform models proteins per tissue, binding sites per tissue, a broad range of predictable side effects, regulatory pathways, and multiple tissue types, enabling deep mechanistic insight into compound behavior.
• The approach bridges computational and experimental research, supporting teams from early dry-lab screening through to final candidate nomination ahead of clinical trials.
• Virtual drug testing using AI and whole-cell simulations is positioned as a next-generation approach capable of complementing or reducing reliance on traditional lab experiments.

Notable Details and Research Focus

• Cytocast launched its three flagship products — Screener™, Optimizer™, and Nominator™ — to bring earlier and more interpretable safety insights to drug discovery and preclinical decision-making.
• The company has published research and blog content covering topics such as virtual drug testing, AI-driven cell simulations, and the neurological impacts of COVID-19, including microglial dysfunction and CNS inflammation.
• Cytocast has participated in high-profile industry events, including JPM Week in San Francisco, reflecting its active engagement with the pharmaceutical and investment communities.
• The company is structured with a core team, investors, advisors, and a body of scientific publications, underscoring its commitment to rigorous, research-backed development.

Cytocast serves pharmaceutical research teams seeking to make smarter, faster, and safer decisions throughout the drug discovery and preclinical development process, with the ultimate goal of reducing the risk of adverse outcomes in clinical trials and bringing safer drugs to patients more efficiently.